Blood thinners increase perioperative complication risk

Article

Use of warfarin or clopidogrel is associated with a significant increase in non-sight-threatening complications during cataract surgery, concluded a study published in the January issue of Eye.

Use of warfarin or clopidogrel is associated with a significant increase in non-sight-threatening complications during cataract surgery, concluded a study published in the January issue of Eye.

Rob L. Johnston, of the Gloucestershire Eye Department, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, Gloucestershire, UK and colleagues remotely used the Cataract National Dataset to extract and analyse data on 48,862 operations for which other pharmaceutical information was available, and assessed how these drugs impacted complication rates. The operations assessed were conducted across eight National Health Service (NHS) centres between 2001 and 2006; 28.1% of the patients studied were taking aspirin, 5.1% were taking warfarin, 1.9% were taking clopidogrel and 1.0% were taking dipyridamole.

The data showed that 8.0% of clopidogrel users reported sharp needle or subtenon’s cannula local anaesthetic block. This compares with 6.2% of warfarin users and 4.3% of other patients. The incidence of sight-threatening complications, however, was similar across all groups. The incidence of subconjunctival haemorrhage was 4.4% for clopidogrel users, 3.7% for warfarin users and 1.7% of other patients. Posterior capsular rupture (PCR) incidence was 3.23% in clopidogrel users and 1.77% for other patients. Overall, 7.3% of clopidogrel users experienced a perioperative complication, compared with 4.4% of other patients.

The researchers concluded that use of either clopidogrel or warfarin increased the likelihood of sharp needle or subtenon’s cannula during cataract surgery, although the risk of sight-threatening or haemorrhagic complications was not increased.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.